Comvita says Derma Sciences, its global licensee for Medihoney wound care products, is now generating more than $US7 million US in sales per year.
Under the terms of the licensing agreement, Derma Sciences will pay Comvita $US1 million at the end of the month.
Comvita has an 8% ownership of Derma Sciences, which is listed on the Nasdaq index in New York.
Shares in Comvita were unchanged at $1.60 on Tuesday.
